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Abstract
Background
Fingolimod efficiently reduces multiple sclerosis (MS) relapse by inhibiting lymphocyte
egress from lymph nodes through down-modulation of sphingosine 1-phosphate (S1P) re-
ceptors. We aimed to clarify the alterations in peripheral blood T cell subsets associated
with MS relapse on fingolimod.
Methods/Principal Findings
Blood samples successively collected from 23 relapsing-remitting MS patients before and
during fingolimod therapy (0.5 mg/day) for 12 months and 18 healthy controls (HCs) were
analysed for T cell subsets by flow cytometry. In MS patients, the percentages of central
memory T (CCR7+CD45RO+) cells (TCM) and naïve T (CCR7+CD45RO-) cells decreased
significantly, while those of effector memory T (CCR7-CD45RA-) and suppressor precursor
T (CD28-) cells increased in both CD4+T and CD8+T cells from 2 weeks to 12 months during
fingolimod therapy. The percentages of regulatory T (CD4+CD25highCD127low) cells in
CD4+T cells and CCR7-CD45RA+T cells in CD8+T cells also increased significantly. Eight
relapsed patients demonstrated greater percentages of CD4+TCM than 15 non-relapsed
patients at 3 and 6 months (p=0.0051 and p=0.0088, respectively). The IL17-, IL9-, and IL4-
producing CD4+T cell percentages were significantly higher at pre-treatment in MS patients
compared with HCs (p<0.01 for all), while the IL17-producing CD4+T cell percentages
tended to show a transient increase at 2 weeks of fingolimod therapy (pcorr=0.0834).
Conclusions
The CD4+TCM percentages at 2 weeks to 12 months during fingolimod therapy are related
to relapse.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system
and is assumed to be an autoimmune disease targeting myelin [1]. Fingolimod efficiently re-
duces MS relapse by inhibiting lymphocyte egress from lymph nodes through down-
modulation of sphingosine 1-phosphate (S1P) receptors [2,3], which is consistent with findings
in an animal model of MS that fingolimod successfully reduced the infiltration of myelin anti-
gen-specific CD4+T cells into inflammatory sites in experimental autoimmune encephalomy-
elitis [4]. Fingolimod traps CD45RO+ central memory T cells (TCM) and naïve T cells
expressing homing receptors for lymph nodes, CCR7 and CD62L, within lymph nodes [5]. The
drug is supposed to exert its effects by inhibiting recirculation of TCM, which include autoreac-
tive T cells [6]. Although fingolimod was also found to be beneficial in a controlled trial for
human renal transplantation [7], its effects have not been examined for any other autoimmune
diseases in large-scale clinical trials.
MS is now assumed to be a T helper 1 (Th1)/Th17-mediated autoimmune disease [1]. Some
authors reported a decrease in IL17-positive cells in MS patients on fingolimod 1.25 mg once
daily at the long-term therapy stage, but not on IFNβ [8], while others reported an increase in
IL17-producing cells in a considerable fraction of MS patients on fingolimod 0.5 mg once daily
at the short-term treatment stage [9]. In addition, effector memory T cells (TEM) without
CCR7, which reside in non-lymphoid organs and mainly comprise IFNγ-producing Th1 cells
protecting against infection, were found to show a relative increase during fingolimod therapy
[7], while other authors reported TEM as the principal IL17-producing T cells [10]. Thus, the
short-term and long-term effects of fingolimod on Th17 cells at an ordinary dosage (0.5 mg/
day) remain to be elucidated. Therefore, we aimed to clarify the alterations in peripheral blood
T cell subsets during short-term and long-term treatment periods, which are associated with
therapeutic efficacy or treatment failure including suboptimal responses during
fingolimod therapy.
Materials and Methods
Patients and control subjects
Venous blood samples were obtained from 18 healthy controls (HCs) (12 females and 6 males;
mean age ± SD, 41.2±12.2 years) and 23 relapsing-remitting MS patients (15 females and
8 males; mean age ± SD, 42.3±12.5 years) who were started on fingolimod therapy between
2012 and 2014 at Kyushu University Hospital after informed consent was obtained (Table 1).
In the latter, blood was withdrawn before and at 2 weeks and 1, 2, 3, 6, and 12 months after ini-
tiation of fingolimod 0.5 mg once daily. MS was diagnosed based on the 2005 revised McDon-
ald criteria for MS [11] and all patients were seronegative for anti-aquaporin-4 (AQP4)
antibodies [12,13]. Ten patients had neither immunomodulatory drugs nor corticosteroids
within 3 months before the initiation of fingolimod, two had IFNβ-1b until 10 days and 1 day
before fingolimod initiation, respectively, one had IFNβ-1a until 14 days before, and nine had
prednisolone until 1 day before. All MS patients underwent a neurological examination at our
outpatient clinic at 2–4-week intervals and were evaluated by the Expanded Disability Status
Scale of Kurtzke (EDSS) [14] with calculation of the Progression Index [15], and observed for
the emergence of clinical relapse. Clinical relapse was defined as the appearance of new symp-
toms or return of old symptoms for a period of 24 hours or more in the absence of a change in
the core body temperature or infection [16]. Brain and spinal cord MRI was performed at
6 and 12 months after initiation of fingolimod to determine the presence of new/enlarging T2
lesions and gadolinium-enhanced T1 lesions (MRI relapse) [16]. All MRI studies were
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performed using a 1.5 T unit (Magnetom Vision and Symphony; Siemens Medical Systems, Er-
langen, Germany) as previously described [17]. This study was approved by the Kyushu Uni-
versity Hospital Ethics Committee. All individuals involved in this study signed a written
informed consent form (Approval Number: 575–03).
Antibodies and flow cytometry
T cells were analysed in whole blood specimens using the following antibodies fromMiltenyi
Biotec (Auburn, CA): anti-human CD3-VioBlue (BW264/56, MACS), CD4-APC (M-T466,
MACS), CD8-APC (BW135/80, MACS), CD45RO-FITC (UCHL1, MACS), CD45RA-APC-
Vio770 (T6D11, MACS), CD127-FITC (MB15-18C9, MACS), CD25-PE (4E3, MACS),
CCR7-PE (FR11-11E8, MACS), CD8-PE (BW135/80, MACS), CD4-FITC (M-T466, MACS),
and CD28-APC (15E8, MACS). The following isotype controls fromMiltenyi Biotec were also
used: anti-mouse IgG1-PE (IS5-21F5, MACS), IgG1-APC (IS5-21F5, MACS), IgG1-FITC (IS5-
21F5, MACS), IgG2a-APC (S43.10, MACS), IgG2a-VioBlue (S43.10, MACS), IgG2a-PE
(S43.10, MACS), IgG2a-FITC (S43.10, MACS), IgG2b-APC-Vio770 (IS6-11E5.11, MACS),
IgG2b-PE (IS6-11E5.11, MACS), and IgG2b-FITC (IS6-11E5.11, MACS). Specific cytokine-
producing cells and chemokine receptor-positive cells were analysed using the following anti-
bodies: anti-human CD4-APC (M-T466, MACS; Miltenyi Biotec), CD8-VioBlue (BW135/80,
MACS; Miltenyi Biotec), IFNγ-FITC (25723.11; BD Biosciences, San Jose, CA), IL17-PE
(BL168; Biolegend, San Diego, CA), IL4-FITC (MP4-25D2; Biolegend), and IL9-PE (AH9R7;
Biolegend). Peripheral blood mononuclear cells (PBMCs) were isolated with Lymphoprep
Tubes (AXIS-SHIELD Poc AS, Oslo, Norway). For intracellular cytokine detection, PBMCs
were stimulated with phorbol 12-myristate 13-acetate (10 ng/ml) and ionomycin (1 μg/ml)
(both from Enzo Life Sciences, Plymouth Meeting, PA) in the presence of brefeldin A (Sigma-
Aldrich, St. Louis, MO) for 4 h at 37°C in 5% CO2, fixed, and permeabilised with BD FACS lys-
ing solution and BD FACS permeabilising solution (BD Biosciences) according to the manu-
facturer’s instructions. Data were acquired using a FACScan flow cytometer (MACSQuant
Analyzer; Miltenyi Biotec) according to standard procedures for whole blood samples and
PBMCs, as described previously [18,19]. Naïve T (CCR7+CD45RO-) cells, TCM
(CCR7+CD45RO+), TEM (CCR7-CD45RA-), CD8+CD45RA+effector memory T (CD8+
CCR7-CD45RA+) cells (TEMRA), regulatory T (CD4+CD25highCD127low) cells (Treg), and
suppressor precursor T (CD28-) cells (Ts) were measured in all 23 patients in S1 Fig, while
IFNγ-, IL17-, IL9-, and IL4-producing cells were analysed in 16 patients.
Table 1. Demographic features of the subjects.
HCs MS PT MS during fingolimod
treatment for 12 months
Relapsed patient Non-relapsed patient
Sex (male: female) 6: 12 8: 15 3: 5 5: 10
Age at examination (mean ± SD, years) 41.2 ± 12.2 42.3 ± 12.5 35.6 ± 13.3 40.0 ± 11.9
Age at Onset (mean ± SD, years) NA 28.9 ± 12.4 28.1 ± 12.4 28.7 ± 12.8
Disease duration (mean±SD, years) NA 11.2 ± 9.7 7.3 ± 8.1 13.2 ± 10.1
Annualised relapse rate (mean ± SD, /years) NA 3.3 ± 3.0 2.9 ± 3.0 3.5 ± 3.1
EDSS scores before fingolimod treatment (mean ± SD) NA 2.8 ± 2.1 2.5 ± 2.3 3.2 ± 2.1
Progression Index (mean ± SD) NA 0.6 ± 1.0 0.9 ± 1.6 0.4 ± 0.4
Abbreviations: HCs = healthy controls; MS PT = multiple sclerosis at pre-treatment; EDSS = Expanded Disability Status Scale of Kurtzke.
doi:10.1371/journal.pone.0124923.t001
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Statistical analysis
Demographic features between MS patients and HCs and between MS patients with and with-
out relapse on fingolimod were compared by the Mann—Whitney U test, except for the sex
ratio compared by Fisher’s test. T cell counts and subset percentages between MS patients and
HCs, between pre-treatment and post-treatment values in MS patients, and between MS pa-
tients with and without relapse on fingolimod were compared by the Mann—Whitney U test.
For independent multiple comparisons, uncorrected p (puncorr) values were multiplied by the
number of comparisons to calculate corrected p (pcorr) values (Bonferroni—Dunn’s correction).
Values of p<0.05 were considered to indicate statistical significance.
Results
Demographic features and treatment response to fingolimod
During fingolimod therapy, four patients had mild liver dysfunction and three patients had
lymphopenia (less than 200 /μl), all of which recovered after cessation of the drug or symptom-
atic treatment. Also during fingolimod therapy, two patients had clinical relapses (both at 3
months after initiation of the drug) and six patients had new gadolinium-enhanced lesions on
T1-weighted MRI or new/enlarging lesions on T2-weighted images at 6 or 12 months after ini-
tiation of the drug. These eight patients were classified as a relapsed group, while the remaining
15 patients were classified as a non-relapsed group. Although the relapsed patients had a
shorter disease duration and higher Progression Index than the non-relapsed patients, there
were no significant differences in any of the demographic features examined between the re-
lapsed and non-relapsed patients (Table 1).
Comparisons of T cell subsets between MS patients at pre-treatment
and HCs
There were no significant differences in the counts of lymphocytes, CD4+T cells, and CD8+T
cells and the percentages of CD4+T cells between the MS patients at pre-treatment and HCs,
while the percentage of CD8+T cells was significantly lower in MS patients than in HCs
(p<0.05) (Fig 1A–1C). In addition, there were no significant differences in the percentages of
naïve T cells, TCM, TEM, Treg, and Ts in CD4+T cells and naïve T cells, TCM, TEM, TEMRA,
and Ts in CD8+T cells between the MS patients at pre-treatment and HCs (Fig 2A and 2B).
Alterations in T cell subsets during fingolimod therapy
The total lymphocyte counts were markedly decreased from 2 weeks until 12 months after ini-
tiation of fingolimod (Fig 1A), and the absolute counts and percentages of CD4+T cells and the
counts of CD8+T cells were also decreased (Fig 1B and 1C). The absolute counts of TCM, naïve
T cells, and TEM in both CD4+T and CD8+T cells and Treg in CD4+T cells decreased signifi-
cantly from 2 weeks to 12 months compared with the pre-treatment levels (p<0.0001 for all),
as shown in S2 Fig.
In CD4+T cells, the percentages of TCM and naïve T cells decreased significantly from 2
weeks to 12 months compared with the pre-treatment levels (p<0.0001 for all), while the TEM
and Ts percentages increased from 2 weeks to 12 months compared with the pre-treatment lev-
els (p<0.0001 for all) and the Treg percentages also increased from 2 weeks to 1 month
(p<0.05) (Fig 2A). In CD8+T cells, the percentages of naïve T cells and TCM decreased signifi-
cantly from 2 weeks to 12 months compared with the pre-treatment levels, while the TEMRA
and Ts percentages increased from 2 weeks to 12 months (p<0.0001 for all) (Fig 2B). However,
the TEM percentages in CD8+T cells showed no significant changes.
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Comparisons of specific cytokine-producing T cell percentages between
MS patients at pre-treatment and HCs
The percentages of IL17-, IL9-, and IL4-producing cells in CD4+T cells were significantly
higher in MS patients than in HCs (p<0.01 for all), and the percentages of IFNγ-, IL17-, IL9-,
and IL4-producing cells in CD8+T cells were also significantly higher in MS patients than in
HCs (p<0.05, p<0.01, p<0.01, and p<0.05, respectively) (Fig 3). These trends were observed
in IL17-, IL9-, and IL4-producing CD4+T and CD8+T cells in the MS patients, irrespective of
whether they had IFNβ or corticosteroids within 3 months of initiation of fingolimod, as
shown in S3 Fig. However, the increases in IFNγ-producing CD4+T and CD8+T cells at pre-
treatment were only significant in the MS patients without IFNβ or corticosteroids.
Alterations in specific cytokine-producing T cell percentages during
fingolimod therapy
The percentages of IFNγ-producing cells in both CD4+T and CD8+T cells and those of
IL17-producing cells in CD4+T cells increased transiently at 2 weeks after initiation of
Fig 1. Counts of lymphocytes, CD4+T, and CD8+T cells are decreased from 2 weeks. Effects of
fingolimod on peripheral blood lymphocyte counts (A) and absolute numbers and percentages of CD4+T (B)
and CD8+T (C) cells in lymphocytes of healthy controls (HCs) and MS patients at pre-treatment (MS PT) and
the indicated periods of fingolimod treatment. The numbers examined at each time point were: HC = 18, and
MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23, 6M = 20, 12M = 18. The horizontal bars indicate the mean
values. W = week; M = month. ***p<0.0001, *p<0.05.
doi:10.1371/journal.pone.0124923.g001
T Cell Dynamics in Multiple Sclerosis Patients on Fingolimod
PLOSONE | DOI:10.1371/journal.pone.0124923 April 28, 2015 5 / 13
fingolimod (puncorr<0.05 for all, but not significant after correction for multiple comparisons
except that IL17-producing CD4+T cells showed an increased tendency at 2 weeks, pcorr =
0.0834), and thereafter decreased gradually to the pre-treatment levels after 3 months (Fig 3).
These changes were observed regardless of prior treatment with IFNγ or prednisolone (data
not shown). In contrast, IL17-producing CD8+T cells, and IL4- and IL9-producing CD4+T and
CD8+T cells showed no such transient increases after the introduction of fingolimod. However,
Fig 2. The percentages of T cell subsets show significant changes from 2 weeks. Effects of fingolimod on phenotypically distinct CD4+T (A) and CD8+T
(B) cell subpopulations in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. Naïve = naïve
T cells (CCR7+CD45RO-); TCM = central memory T cells (CCR7+CD45RO+); TEM = effector memory T cells (CCR7-CD45RA-); Treg = regulatory T cells
(CD4+CD25highCD127low); Ts = suppressor precursor T cells (CD28-); TEMRA = CD8+CD45RA+effector memory T cells (CD8+CCR7-CD45RA+). The
numbers examined at each time point were: HC = 18, and MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23, 6M = 20, 12M = 18. The horizontal bars indicate
the mean values. W = week; M = month. ***p<0.0001, **p<0.01, *p<0.05.
doi:10.1371/journal.pone.0124923.g002
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Fig 3. The IL17-, IL9-, and IL4-producing cells are higher in MS patients than in HCs. Effects of fingolimod on IFNγ- (A), IL17- (B), IL9- (C), and
IL4-producing (D) cells in CD4+T and CD8+T cells in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the indicated periods of fingolimod
treatment. The numbers examined at each time point were: HC = 9, and MS PT = 16, 2W = 12, 1M = 12, 2M = 11, 3M = 12, 6M = 7, 12M = 11. The horizontal
bars indicate the mean values. Open diamonds = MS patients with relapse during fingolimod therapy (n = 2); closed circles = MS patients without relapse
during the therapy (n = 14). W = week; M = month. **p<0.01, *p<0.05.
doi:10.1371/journal.pone.0124923.g003
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the absolute counts of all cytokine-producing T cells in CD4+T cells decreased significantly
from 2 weeks to 12 months compared with the pre-treatment levels (pcorr<0.05 for all), as
shown in S4 Fig.
Correlations of alterations in distinct T cell subsets and specific cytokine-
producing T cells during fingolimod therapy with treatment response
When the relapsed and non-relapsed MS patients were compared, only the percentages of
CD4+TCM differed significantly between the two groups. Specifically, the relapsed patients
had significantly greater percentages of CD4+TCM than the non-relapsed patients at 3 and
6 months (p = 0.0051 and p = 0.0088, respectively) (Fig 4).
Discussion
This study is the first to successively assess the dynamics of T cell subsets from 2 weeks up to
12 months of fingolimod therapy in MS patients. Although selection bias was not completely
eliminated, no selection was made on referral to our clinic for initiation of fingolimod treat-
ment. In addition, clinical and MRI relapses were seen in 8.7% and 26.1% of our patients, re-
spectively, at 0–12 months. These findings are consistent with the observations in a Japanese
clinical trial of fingolimod 0.5 mg once daily, in which clinical relapses occurred in 15.6% at
0–6 months and 6.7% at 7–12 months, while gadolinium-enhanced T1 lesions appeared in
22.2% at 0–6 months and 15.6% at 7–12 months and new/enlarging T2 lesions appeared in
33.3% at 0–6 months and 13.3% at 7–12 months [20]. Therefore, we believe that the recruit-
ment of MS patients did not severely distort our findings.
The reductions in TCM and naïve T cells in both CD4+T and CD8+T cells in peripheral
blood occurred very rapidly and continued for as long as fingolimod was administered. Inter-
estingly, among the T cell subsets showing significant alterations during fingolimod therapy,
only the CD4+TCM percentages were associated with MS relapse, although the pre-treatment
TCM percentages in CD4+T cells did not differ significantly between the relapsed and non-
relapsed patients, suggesting a critical role of CD4+TCM cells in MS relapse. The relapsed pa-
tients had a shorter disease duration and higher Progression Index than the non-relapsed pa-
tients in our study, but the differences were not significant, possibly because of the small
sample size. Thus, MS patients in the early course, who are presumed to have high inflammato-
ry disease activity, may tend to show a suboptimal response to fingolimod 0.5 mg once daily be-
cause of an insufficient decrease in CD4+TCM cells. Therefore, careful observation of the
clinical and MRI disease activity may be required when fingolimod is introduced in MS pa-
tients with shorter disease duration and high disease activity. The present findings indicate that
peripheral blood CD4+TCM cell percentages during fingolimod therapy may have a predictive
value for relapse at least during the first year. However, as the present study involved a relative-
ly small cohort, a large-scale confirmatory study will be necessary to establish TCM frequency
as a potential biomarker for the relapse propensity of MS patients on fingolimod treatment.
The increased pre-treatment percentages of IL17-producing CD4+T and CD8+T cells in MS
patients, especially in MS patients without IFNβ or corticosteroids, are consistent with a previ-
ous study showing that peripheral blood Th17 cells increase in Western MS patients [21].
These observations collectively suggest pathogenic roles of IL17-producing T cells in MS. In
our study, the IL17-producing CD4+T cell percentage showed a transient increase in the very
early course of fingolimod therapy, which is partly compatible with the increase in IL17-produ-
cing cells observed in a short-term study of fingolimod [9]. This increase may be explained by
a relative increase in TEM, which contain both Th1 and Th17 cells [10], while the absence of
replenishment of Th1 and Th17 cells by naïve T cells that are continuously trapped in lymph
T Cell Dynamics in Multiple Sclerosis Patients on Fingolimod
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nodes may limit the persistence of the increase [6,22]. Importantly, this transient increase in
the IL17-producing cell percentage was not associated with the development of relapse, at least
in anti-AQP4 antibody-seronegative MS patients. In contrast, unexpected relapse was reported
to occur in the early course of anti-AQP4 antibody-positive patients with neuromyelitis optica
Fig 4. The relapsed patients have greater percentages of CD4+TCM at 3 and 6 months. Comparisons of TCM (A) and TEM (B) percentages in CD4+T
cells at pre-treatment (MS PT) and the indicated periods of fingolimod treatment between MS patients with (open diamonds) and without (closed circles)
relapse during the therapy. Box-whisker plots are shown. W = week; M = month.
doi:10.1371/journal.pone.0124923.g004
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(NMO) [19,23] and tumefactive MS patients [24,25]. As an increase in IL17 in CSF was ob-
served in NMO patients at relapse [26–28], it is possible that the transient increase in the
IL17-producing cell percentage may play a role in these conditions with fingolimod therapy.
Compared with HCs, IFNγ-, IL4-, and IL9-producing CD4+T and CD8+T cells were in-
creased in MS patients at pre-treatment, especially in the MS patients without IFNγ or cortico-
steroids. Increases in IFNγ-producing CD4+T and CD8+T cells were previously reported in
Western and Asian MS patients [29,30], consistent with the induction of MS relapse by admin-
istration of IFNγ [31]. The increase in IL4-producing cells in the remission phase of MS pa-
tients may be a host defence mechanism. In our hands, fingolimod did not appear to down-
regulate IL4-producing cells, which may be beneficial for Th1/Th17-mediated diseases like MS
[1]. IL9-producing cells at pre-treatment may have been influenced by disease-modifying
therapies such as IFNβ [32], which was reported to potentiate IL9 production via IL21 in
Th9-polarising conditions in humans [33]. However, as the MS patients without IFNβ also had
greater percentages of IL9-producing CD4+T and CD8+T cells, such increases may have some
relevance to MS mechanisms. Although IL9 was previously regarded as one of the Th2 type cy-
tokines, it was recently reported that IL9-producing CD4+T cells can induce neuroinflamma-
tion in certain conditions [34] and that Th17 cells can produce IL9, which exacerbates
experimental autoimmune encephalomyelitis [35]. Therefore, increases in IL9-producing T
cells in MS patients may warrant to careful monitoring to clarify the relationship between
IL9-producing T cell changes and relapse while on fingolimod therapy.
Finally, Treg and Ts are subpopulations of T cells that down-regulate immune response and
autoimmune disease activities [36,37]. However, we did not find any differences in these cell
percentages between the relapsed and non-relapsed MS patients during fingolimod therapy.
Although the relative increases in these cells may have some roles in down-modulating the dis-
ease activity of MS during fingolimod treatment, these cell percentages are not useful as predic-
tors of relapse.
Supporting Information
S1 Dataset. Actual values for percentages and counts of T cell subsets in healthy controls
and patients with multiple sclerosis. (Sheet 1) The rows show the actual values for the per-
centages and counts of T cell subsets in individual samples. T cells are classified by their surface
antigens. H1–H18 are healthy controls (HCs) and P1–P23 are patients with multiple sclerosis
(MS). Figs 1, 2, 4, and S2 are based on these values. (Sheet 2) The rows show the actual values
for the percentages and counts of T cell subsets in individual samples. T cells are classified by
their cytokine productions. H1–H9 are HCs and P1–P16 are patients with MS. Figs 3, S3, and
S4 are based on these values. The clinical statuses and timings of sample collection before or
after induction of fingolimod treatment are also shown in each patient. EDSS = expanded dis-
ability status scale of Kurtzke; F = female; M = male; NT = not treated; WBC = white
blood cells.
(XLSX)
S1 Fig. Gating of cells in the flow cytometry studies. First, lymphocytes were gated as forward
scatter-medium and side scatter-low populations (A), and CD4+T cells were gated as indicated
in (B). The cells were then gated to discriminate central memory T cells (TCM), effector mem-
ory T cells (TEM), regulatory T cells (Treg), and suppressor precursor T cells (Ts). To deter-
mine the threshold for the CCR7+ and CCR7- populations, we used a PE-conjugated mouse
IgG1 isotype control (C). The cells were then separated by CD45RO and CCR7 to detect
CCR7+CD45RO+ TCM, CCR7-CD45RO+ TEM, and CCR7+CD45RO- naïve T cells (D). To de-
termine the threshold for the CD25+ and CD25- populations, we used a PE-conjugated mouse
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IgG2b isotype control (E). The CD4+ populations were then separated by CD25 and CD127 to
discriminate CD127lowCD25high Treg (F). We also used an APC-conjugated mouse IgG1 iso-
type control (G) to determine the threshold for the CD28+ and CD28- populations to separate
CD4+CD28- Ts (H).
(TIFF)
S2 Fig. The counts of T cell subsets are significantly decreased from 2 weeks. Effects of fin-
golimod on the absolute counts of phenotypically distinct CD4+T (A) and CD8+T (B) cell sub-
populations in healthy controls (HCs) and MS patients at pre-treatment (MS PT) and the
indicated periods of fingolimod treatment. Naïve = naïve T cells (CCR7+CD45RO-); TCM =
central memory T cells (CCR7+CD45RO+); TEM = effector memory T cells (CCR7-CD45RA-);
Treg = regulatory T cells (CD4+CD25highCD127low); Ts = suppressor precursor T cells
(CD28-); TEMRA = CD8+CD45RA+ effector memory T cells (CD8+CCR7-CD45RA+). The
numbers analysed were: HC = 18, and MS PT = 23, 2W = 20, 1M = 17, 2M = 19, 3M = 23,
6M = 20, 12M = 18. The horizontal bars indicate the mean values. W = week; M = month.
p<0.0001, p<0.01, p<0.05.
(TIFF)
S3 Fig. IFNγ-producing cells at pre-treatment are only significant in the MS patients with-
out IFNβ or corticosteroids. Percentages of IFNγ- (A), IL17- (B), IL9- (C), and IL4-producing
(D) cells among CD4+T and CD8+T cells in MS patients with (MS PT+) and without (MS PT-)
IFNβ or corticosteroids within 3 months of the initiation of fingolimod. The numbers exam-
ined at each time point were: HC = 8, and MS PT- = 6, MS PT+ = 10. Box-whisker plots
are shown.
(TIFF)
S4 Fig. The absolute counts of all cytokine-producing T cells in CD4+T cells are decreased
from 2 weeks. Effects of fingolimod on the absolute counts of IFNγ- (A), IL17- (B), IL9- (C),
and IL4-producing (D) cells in CD4+T and CD8+T cells in healthy controls (HCs) and MS pa-
tients at pre-treatment (MS PT) and the indicated periods of fingolimod treatment. The num-
bers examined at each time point were: HC = 9, and MS PT = 16, 2W = 12, 1M = 12, 2M = 11,
3M = 12, 6M = 7, 12M = 11. The horizontal bars indicate the mean values. W = week;
M = month. p<0.01, p<0.05.
(TIFF)
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